
Patricia LoRusso, DO, PhD, professor of medicine and associate director of Innovative Medicine at Yale Cancer Center, discusses the key questions that still remain regarding combination and sequencing with PARP inhibitors.

Your AI-Trained Oncology Knowledge Connection!


Patricia LoRusso, DO, PhD, professor of medicine and associate director of Innovative Medicine at Yale Cancer Center, discusses the key questions that still remain regarding combination and sequencing with PARP inhibitors.

Published: September 25th 2016 | Updated: